Hypofractionated Radiotherapy Plus GM-CSF, Pomalidomide and Glofitamab for Newly Diagnosed PCNS-DLBCL

Exclusion criteria

• . Loss of CD20 expression in B-cell non-Hodgkin lymphoma.
• . Active acute or chronic hepatitis B or hepatitis C infection, including:
• . Receipt of anti-hematologic malignancy therapy within 2 weeks or within 5 pharmacokinetic half-lives before treatment initiation, whichever is longer.
• . Inadequate bone marrow reserve, defined as platelet count \<30 ×10⁹/L or absolute neutrophil count \<1.0 ×10⁹/L.
• . Clinically significant pulmonary diseases, including:
• . Uncontrolled hypertension despite optimal medical management (systolic blood pressure \>150 mmHg or diastolic blood pressure \>90 mmHg), history of hypertensive crisis, or hypertensive encephalopathy.
• . Symptomatic congestive heart failure (NYHA class II-IV), symptomatic or poorly controlled arrhythmias, congenital long QT syndrome, or corrected QT interval (QTc) \>500 ms (Fridericia correction).
• . Receipt of hypofractionated radiotherapy within 4 weeks before the first treatment. Patients receiving radiotherapy \>4 weeks before enrollment must have no ongoing radiation-related toxicities, no requirement for corticosteroids, and no evidence of radiation pneumonitis, hepatitis, enteritis, or other radiation-related complications.